Tag: False

Eastern District of Kentucky | Medical Equipment Company Pays $7 Million to Resolve False Claims Act Allegations

LEXINGTON, Ky.— United Seating and Mobility, LLC, d/b/a Numotion (Numotion) has paid $7 million to resolve civil allegations that it made false statements in connection with claims for reimbursement it submitted to Kentucky Medicaid, two of Kentucky Medicaid’s Managed Care Organization contractors (MCOs), MO HealthNet (Missouri Medicaid), and D.C. Medicaid.

Numotion is a national supplier of durable medical equipment (DME), such as hospital beds, manual wheelchairs, power wheelchairs and accessories, and gait trainers.  The investigation involved DME that was “manually priced” by Medicaid payors in Kentucky, Missouri, and D.C.  Those Medicaid programs reimbursed manually priced DME based on the cost Numotion actually paid the manufacturer for the equipment.  Specifically, in Kentucky, reimbursement is based on “a manufacturer’s actual charges” billed to Numotion, or the “invoice price;” in Missouri, reimbursement is based on the “actual invoice of cost;” and in D.C., reimbursement is based on “original documentation reflecting all discounts.”

In the Settlement Agreement, the United States alleged that Numotion did not disclose all discounts Numotion received from, or the cost Numotion actually paid to, DME manufacturers when submitting claims for manually priced DME to Kentucky Medicaid, two Kentucky Medicaid MCOs (Aetna Better Health of Kentucky and WellCare of Kentucky), MO HealthNet, and D.C. Medicaid.  Numotion’s failure to disclose all discounts, or the actual cost paid, resulted in these Medicaid programs paying Numotion higher reimbursements than it was entitled to receive.  The United States contended that the conduct violated the False Claims Act, 31 U.S.C. § 3729(a)(1)(B), a federal law that prohibits knowingly making or using a false statement material to a false claim for reimbursement. 

As part of the settlement, Numotion also entered into a 5-year Corporate Integrity Agreement (CIA) with the U.S. Department of Health and Human Services Office of Inspector General.  The CIA requires, among other things, that Numotion implement a centralized risk assessment program, as part of its compliance program, and hire an Independent Review Organization to complete annual reviews of some of its Medicare and Medicaid claims.

“By hiding or failing to disclose discounts, to receive higher reimbursement from Medicaid programs across the country, Numotion prioritized its financial incentives, to the detriment of these Medicaid programs,” said Carlton S. Shier, IV, United States Attorney for the Eastern District of Kentucky.  “Whenever the valuable resources of government health care programs are improperly dissipated to those who are not entitled, it diminishes the ability of these programs to meet the needs of their beneficiaries.  We remain committed to doing our part to protect these programs from fraud, waste, and abuse and to preserve the taxpayer money that supports them.”

“When health care companies do not follow federal health care billing requirements, the integrity of those safety net programs can be undermined,” said Special Agent in Charge Tamala E. Miles of the U.S. Department of Health and Human Services Office of Inspector General.  “Working with our law enforcement partners, the dedicated work of OIG’s investigators and attorneys has again resulted in the recovery of taxpayer dollars and better protection against improper billing in the future.”

The settlement resolves a lawsuit originally brought by L. Richard Parkey, a former Numotion employee, under the qui tam, or whistleblower, provisions of the False Claims Act.  Under those provisions, a private party can file an action on behalf of the United States and receive a portion of any recovery. As part of this resolution, Parkey will receive approximately $1.05 million of the settlement amount.

This case was investigated by the U.S. Department of Health and Human Services, Office of Inspector General.  Assistant United States Attorney Jennifer A. Williams handled the matter for the United States.

The case is United States ex rel. L. Richard Parkey v. United Seating and Mobility, LLC d/b/a Numotion, Case No. 3:17-cv-53-GFVT.  The claims resolved by the settlement are allegations only, and there has been no determination of liability.

 

– END –

Florida Woman Sentenced to Prison for False Statement to Investigator Related to Pediatric Asthma Drug Study | OPA

A federal decide sentenced a Florida girl to jail for building a bogus assertion to a federal government investigator similar to a clinical trial that studied the performance of asthma prescription drugs in youngsters.

Jessica Palacio, 37, of Miami, was convicted by a jury on Sept. 13, 2022, for lying to a U.S. Foodstuff and Drug Administration (Food and drug administration) investigator for the duration of a 2017 regulatory inspection of the firm conducting the drug demo. On January 12, U.S. District Choose Darrin P. Gayles sentenced Palacio to 36 months in jail and 3 yrs of supervised launch.

In accordance to evidence presented at trial, Palacio worked from 2013 to 2015 as a clinical exploration coordinator at a scientific trial company in Miami called Unrestricted Health care Research (UMR). UMR was a single of several organizations hired to carry out a scientific trial made to look into the basic safety of an asthma medicine in kids. The drug company discovered difficulties in the demo done by the business dependent on a evaluation of data and notified the Fda.

In May well 2021, a grand jury in Miami returned a two-count indictment versus Palacio alleging a scheme to falsify health-related information to make it show up as although pediatric subjects made scheduled visits to UMR, gained physical exams from a scientific investigator, and took study medicine as expected, when in fact these activities experienced not happened. The indictment alleged that when Palacio was confronted by an Fda regulatory investigator about her job in the clinical demo conducted by UMR, she submitted a untrue affidavit saying that she experienced executed a screening check out of a child topic when she experienced not.

Following demo, the jury located Palacio responsible of each conspiring to commit wire fraud and with earning a bogus assertion. The courtroom subsequently granted a defense motion for a judgment of acquittal on the conspiracy charge but denied a motion for judgment of acquittal as to the untrue statement charge.

“Clinical trials perform a essential position in establishing drug protection and efficacy,” claimed Principal Deputy Assistant Lawyer Typical Brian M. Boynton, head  of the Justice Department’s Civil Division. “The Justice Department will work closely with its regulation enforcement companions to defend the integrity of this essential system.”

“Reliable and correct info from scientific trials is the cornerstone of FDA’s evaluation of a new drug,” mentioned Specific Agent in Demand Justin C. Fielder in the Fda Business of Criminal Investigations Miami Industry Place of work. “Compromised clinical trial details could impression the agency’s choices about the safety and effectiveness of the drug below review. Today’s sentencing demonstrates that those who attempt to subvert the regulatory capabilities of the Fda by creating fake statements to the agency to address up falsified information will be held accountable for their steps.”

4 co-conspirators earlier pleaded responsible and have been sentenced for their roles in the plan at UMR. Yvelice Villaman Bencosme, M.D., 66, of Miami, was sentenced to 36 months’ imprisonment, and Lisett Raventos, 48, also of Miami, was sentenced to 30 months’ imprisonment. In addition, Maytee Lledo, 52, of Hialeah, Florida, was sentenced to 14 months’ imprisonment, which the court later on modified to time served, and Olga Torres, 50, of Miami, was sentenced to 3 years’ probation.    

The Food and drug administration Business of Criminal Investigations investigated the scenario.

The scenario was prosecuted by Senior Litigation Counsel David A. Frank and Trial Lawyer Marilee L. Miller from the Civil Division’s Buyer Defense Department, with the support of Associate Chief Kyrsten Melander for Enforcement at FDA’s Place of work of Chief Counsel.